Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech Names John Whiting Vice President

South San Francisco, Calif. -- January 11, 2001 --

Genentech, Inc. (NYSE: DNA) today announced the promotion of John Whiting to vice president. In this position, he will continue to serve as Genentech's controller and chief accounting officer. Whiting reports directly to Louis J. Lavigne, Jr., executive vice president and chief financial officer.

"During his nearly 12 years at Genentech, John has played a critical role in the financial success of our business," said Lavigne. "This well-deserved promotion recognizes his astute financial expertise, as well as his ability to strengthen and unify the Controller's organization throughout the company."

Whiting, 45, has held several positions at Genentech since joining the company in 1989. Prior to being appointed controller and chief accounting officer in 1997, he served as director of corporate financial planning and analysis.

Whiting holds a master's degree in business administration and a bachelor of science degree from the University of Oregon.

Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved products of biotechnology stem from Genentech science. Genentech markets nine products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.